Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Buy
83
TAK Quote, Financials, Valuation and Earnings
Last price:
$18.49
Seasonality move
:
-3.96%
Day range:
$18.36 - $18.50
52-week range:
$12.99 - $18.50
Dividend yield:
3.58%
P/E ratio:
76.66x
P/S ratio:
1.96x
P/B ratio:
1.20x
Volume:
3.1M
Avg. volume:
3.3M
1-year change:
35.54%
Market cap:
$58.3B
Revenue:
$30.1B
EPS (TTM):
$0.24
Analysts' Opinion
-
Consensus RatingTakeda Pharmaceutical Co., Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.07, Takeda Pharmaceutical Co., Ltd. has an estimated upside of 3.28% from its current price of $18.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.92 representing 2.92% downside risk from its current price of $18.46.
Fair Value
-
According to the consensus of 3 analysts, Takeda Pharmaceutical Co., Ltd. has 3.28% upside to fair value with a price target of $19.07 per share.
TAK vs. S&P 500
-
Over the past 5 trading days, Takeda Pharmaceutical Co., Ltd. has overperformed the S&P 500 by 4.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Takeda Pharmaceutical Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Takeda Pharmaceutical Co., Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Takeda Pharmaceutical Co., Ltd. reported revenues of $7.7B.
Earnings Growth
-
Takeda Pharmaceutical Co., Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Takeda Pharmaceutical Co., Ltd. reported earnings per share of $0.21.
Enterprise value:
85.1B
EV / Invested capital:
1.07x
Price / LTM sales:
1.96x
EV / EBIT:
24.18x
EV / Revenue:
2.85x
PEG ratio (5yr expected):
5.54x
EV / Free cash flow:
19.56x
Price / Operating cash flow:
13.47x
Enterprise value / EBITDA:
9.84x
Gross Profit (TTM):
$15.4B
Return On Assets:
0.8%
Net Income Margin (TTM):
2.6%
Return On Equity:
1.63%
Return On Invested Capital:
0.98%
Operating Margin:
16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $29.6B | $30.2B | $29.8B | $7.5B | $7.7B | |
| Gross Profit | $15.5B | $16B | $15.4B | $3.9B | $4.2B | |
| Operating Income | $3.3B | $4.1B | $3.5B | $994.6M | $1.2B | |
| EBITDA | $8.7B | $9.1B | $8.6B | $2.2B | $2.5B | |
| Diluted EPS | $0.40 | $0.43 | $0.24 | $0.05 | $0.21 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.5B | $19.7B | $17.2B | $17.5B | $19.9B | |
| Total Assets | $110.3B | $102.4B | $100.9B | $96.1B | $98.3B | |
| Current Liabilities | $15.7B | $17B | $16.2B | $13.3B | $16.7B | |
| Total Liabilities | $64B | $55.5B | $53.1B | $48.9B | $49.5B | |
| Total Equity | $46.3B | $46.8B | $47.8B | $47.2B | $48.8B | |
| Total Debt | $36.7B | $29.7B | $30.5B | $29.9B | $27.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.7B | $7B | $7.3B | $2.4B | $2.3B | |
| Cash From Investing | -$6.1B | -$2.9B | -$2.3B | -$829.3M | -$1.6B | |
| Cash From Financing | -$1.5B | -$2.7B | -$4B | -$4B | -$1.1B | |
| Free Cash Flow | -$1.5B | $4.8B | $4.4B | $2B | $822.4M | |
TAK
Sector
Market Cap
$58.3B
$24M
Price % of 52-Week High
99.78%
48.29%
Dividend Yield
3.58%
0%
Shareholder Yield
7.38%
-1.62%
1-Year Price Total Return
35.54%
-22.92%
Beta (5-Year)
0.014
0.500
Dividend yield:
3.58%
Annualized payout:
$0.67
Payout ratio:
--
Growth streak:
1 years
Technicals
8-day SMA
Buy
Level
$18.05
200-day SMA
Buy
Level
$14.96
Bollinger Bands (100)
Buy
Level
13.77 - 16.41
Chaikin Money Flow
Buy
Level
12.9M
20-day SMA
Buy
Level
$17.23
Relative Strength Index (RSI14)
Buy
Level
79.84
ADX Line
Buy
Level
42.77
Williams %R
Sell
Level
-2.139
50-day SMA
Buy
Level
$16.03
MACD (12, 26)
Buy
Level
4.92
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
21.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1502)
Buy
CA Score
(Annual)
Level (-0.2279)
Buy
Beneish M-Score
(Annual)
Level (-2.6809)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-1.0789)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Stock Forecast FAQ
In the current month, TAK has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TAK average analyst price target in the past 3 months is $19.07.
-
Where Will Takeda Pharmaceutical Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Takeda Pharmaceutical Co., Ltd. share price will rise to $19.07 per share over the next 12 months.
-
What Do Analysts Say About Takeda Pharmaceutical Co., Ltd.?
Analysts are divided on their view about Takeda Pharmaceutical Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Takeda Pharmaceutical Co., Ltd. is a Sell and believe this share price will drop from its current level to $17.92.
-
What Is Takeda Pharmaceutical Co., Ltd.'s Price Target?
The price target for Takeda Pharmaceutical Co., Ltd. over the next 1-year time period is forecast to be $19.07 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TAK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Takeda Pharmaceutical Co., Ltd. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TAK?
You can purchase shares of Takeda Pharmaceutical Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Takeda Pharmaceutical Co., Ltd. shares.
-
What Is The Takeda Pharmaceutical Co., Ltd. Share Price Today?
Takeda Pharmaceutical Co., Ltd. was last trading at $18.49 per share. This represents the most recent stock quote for Takeda Pharmaceutical Co., Ltd.. Yesterday, Takeda Pharmaceutical Co., Ltd. closed at $18.46 per share.
-
How To Buy Takeda Pharmaceutical Co., Ltd. Stock Online?
In order to purchase Takeda Pharmaceutical Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TAK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TAK
Sector
P/E ratio
76.66x
23.44x
PEG ratio
5.54x
-0.01x
P/B ratio
1.20x
1.73x
Price / LTM sales
1.96x
1.51x
Growth Metrics
TAK
Sector
Revenue growth
3.02%
3.31%
Earnings growth
339.12%
10.7%
Revenue (5-year growth)
-0.14%
6.28%
Earnings forecast
--
-$0.19
Profitability
TAK
Sector
Profitability FY 2024
$16.1B
$2.6M
Return on invested capital
0.98%
-33.62%
Return on assets
0.8%
-29.74%
Return on equity
1.63%
-39.33%
Earnings Date
Last Earnings Date
Jan
29
Next Earnings Date
May
13
Estimated Next Earnings Date
Apr
30
Balance Sheet
TAK
Sector
Total cash
$4.2B
$25M
Short term investments
$136.8M
$23.9M
Total assets
$95.3B
$71.9M
Long term debt
$27.2B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
